AB Science SA (FR:AB)
:AB
Want to see FR:AB full AI Analyst Report?
Top Page
AB Science SA
(AB)
Select Model
Select Model
Rating:40Underperform
Price Target:
€0.99
▼(-32.84% Downside)
Action:Downgraded
Date:05/15/26
The score is held down primarily by weak financial performance (persistent losses, negative equity, and renewed free-cash-flow burn), which drives elevated solvency and funding risk. Technicals also remain bearish with the stock below major moving averages and negative MACD. Valuation provides limited support because the negative P/E reflects continuing unprofitability and there is no dividend yield data.
Positive Factors
Improving Revenue Trend
Sustained revenue growth into 2025 indicates product or program traction and supports longer-term commercial optionality. A growing top line, even from a small base, reduces binary development risk by validating demand and improving prospects for scaling clinical/commercial efforts over months.
Negative Factors
Persistently Negative Equity
Chronic negative shareholder equity is a structural solvency red flag that constrains financing options and strategic flexibility. It signals accumulated losses that can limit lender and partner appetite and increases the likelihood of dilutive capital raises to sustain operations over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving Revenue Trend
Sustained revenue growth into 2025 indicates product or program traction and supports longer-term commercial optionality. A growing top line, even from a small base, reduces binary development risk by validating demand and improving prospects for scaling clinical/commercial efforts over months.
Read all positive factors
AB Science SA (AB) vs. iShares MSCI France ETF (EWQ)
Market Cap
€67.40M
Dividend YieldN/A
Average Volume (3M)323.75K
Price to Earnings (P/E)―
Beta (1Y)1.01
Revenue Growth9.51%
EPS Growth73.33%
CountryFR
Employees40
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.04
Shares Outstanding69,776,230
10 Day Avg. Volume89,975
30 Day Avg. Volume323,750
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)-5.48
Price to Sales (P/S)80.33
P/FCF Ratio-20.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€1.20M
AB Science SA Business Overview & Revenue Model
Company Description
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase...
How the Company Makes Money
null...
AB Science SA Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
22
Negative
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.17M | 1.07M | 970.00K | 958.00K | 1.61M |
| Gross Profit | 720.00K | 1.25M | 587.00K | 927.00K | 1.50M |
| EBITDA | -1.22M | -4.92M | -12.80M | -13.41M | -17.36M |
| Net Income | -1.56M | -7.83M | -10.05M | -13.62M | -14.46M |
Balance Sheet | |||||
| Total Assets | 24.52M | 23.18M | 25.50M | 23.84M | 21.27M |
| Cash, Cash Equivalents and Short-Term Investments | 10.18M | 7.99M | 6.07M | 7.27M | 8.72M |
| Total Debt | 4.24M | 18.47M | 19.10M | 23.96M | 8.35M |
| Total Liabilities | 34.34M | 46.93M | 46.51M | 59.51M | 44.47M |
| Stockholders Equity | -17.20M | -23.75M | -21.01M | -35.67M | -23.20M |
Cash Flow | |||||
| Free Cash Flow | -4.57M | 370.00K | -17.22M | -18.11M | -17.74M |
| Operating Cash Flow | -4.29M | 525.00K | -16.87M | -17.47M | -17.18M |
| Investing Cash Flow | -224.00K | -136.00K | -614.00K | -360.00K | -590.00K |
| Financing Cash Flow | 6.69M | 1.53M | 16.27M | 16.39M | 5.84M |
AB Science SA Technical Analysis
Negative
1.48
Price Trends
1.13
Negative
1.25
Negative
1.25
Negative
Market Momentum
-0.05
Negative
37.08
Neutral
31.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:AB, the sentiment is Negative. The current price of 1.48 is above the 20-day moving average (MA) of 1.04, above the 50-day MA of 1.13, and above the 200-day MA of 1.25, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 37.08 is Neutral, neither overbought nor oversold. The STOCH value of 31.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:AB.
AB Science SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | €92.31B | 15.43 | 8.39% | 4.77% | 6.20% | -3.82% | |
67 Neutral | €13.20B | 22.37 | 10.82% | 1.17% | 8.10% | 28.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €184.05M | -1.31 | -658.91% | ― | -77.92% | 11.11% | |
49 Neutral | €111.38M | -1.28 | -52.76% | ― | -96.28% | -197.89% | |
48 Neutral | €230.14M | -4.72 | -30.75% | ― | 32.62% | -7.59% | |
40 Underperform | €67.40M | -60.57 | ― | ― | 9.51% | 73.33% |
* Healthcare Sector Average
FR:AB
AB Science SA
0.97
-0.37
-27.59%
FR:IPH
Innate Pharma SA
1.96
<0.01
0.41%
FR:IPN
Ipsen
159.60
57.97
57.05%
FR:OSE
OSE Immunotherapeutics SA
4.92
-1.12
-18.51%
FR:SAN
Sanofi
76.67
-12.11
-13.65%
FR:ALCLS
Cellectis SA
3.18
1.84
137.11%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.